Financings in Brief: Medical Device Technologies
This article was originally published in The Gray Sheet
Executive SummaryMedical Device Technologies: Underwriters for the company's June offering of preferred stock and warrants ("The Gray Sheet" July 8, p. 14) exercise an over-allotment option to buy 225,000 redeemable warrants and 100,000 shares of cumulative convertible series A preferred stock. The over-allotment raises $468,000 in additional proceeds for the San Diego-based developer of the Personal Alarm System patient monitoring device, bringing total gross proceeds from the offering to $8.2 mil...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.